Stromal expression of CD10 in breast carcinoma and its correlation with clinicopathological parameters

Dhande, Ashish; Khandeparkar, Siddhi Gaurish Sinai; Joshi, Avinash R; Kulkarni, M. L.; Pandya, Nidhi; Mohanapure, Neelam; Aggarwal, Aakriti; Patil, Gargi

doi:10.4103/sajc.sajc_56_18

Cited by 12 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Epithelial immunoexpression of CD10 was found to be associated with tumor grade, stage, and lymph node invasion in colorectal cancer. 17 On the other hand, the stromal immunoexpression of CD10 was found to be associated with a larger tumor size in colorectal carcinoma, 18 lymph node metastasis, recurrence and disease-free in breast carcinoma, [19][20][21] and gastric carcinoma. 22 Limitations of the study: This study utilized tissue microarray material, which includes representative cores of tissue.…”

Section: Discussionmentioning

confidence: 99%

CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage

Al‐Maghrabi

2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: Primary urinary bladder carcinoma is a common cancer worldwide. There is limited published data about CD10 immunoexpression pattern in urothelial bladder carcinoma (UBC). This study aims to examine CD10 immunoexpression in UBC and evaluate its relationship with clinicopathological parameters. Methods: The retrospective study examined 130 samples of UBC tissue and 30 samples of non-neoplastic urothelial bladder tissue, which were obtained from the Anatomic Pathology Department, King Abdulaziz University, Jeddah, Saudi Arabia. The project started in June 2019 and completed in February 2021. Tissue microarrays (TMA) were prepared from paraffin blocks and tissue sections prepared from the recipient blocks were used for immunohistochemistry studies utilizing CD10 antibody. The immunostaining results were recorded and analyzed. Results: Positive staining of CD10 was observed in 64 (49%) cases of UBC and was not detected in any non-neoplastic urothelium samples. CD10-positive staining was identified in 36.7% and 66.7% of low and high-grade tumors, respectively. There was an association between positive CD10 immunostaining and high tumor grade (p=0.006) and muscularis propria invasion (p=0.007). There was no association between CD10 immunoexpression and age, gender, nodal and distant metastasis, lymphovascular invasion, and tumor recurrence. CD10 immunoexpression was not associated with the probabilities of overall survival (log rank 1.663, p=0.197) or disease-free survival (log rank 1.637, p=0.201). Conclusions: In UBC, CD10 immunoexpression is associated with higher tumor grade and muscle invasion, but it is not associated with patient survival or other clinicopathological parameters. CD10 immunoexpression cannot be used as a biomarker for poor prognosis in UBC. doi: https://doi.org/10.12669/pjms.39.1.6268 How to cite this: Al-Maghrabi J. CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage. Pak J Med Sci. 2023;39(1):---------. doi: https://doi.org/10.12669/pjms.39.1.6268 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 99%

CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage

Al‐Maghrabi

2022

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…There are some previous studies concluding that stromal expression of CD10 is an obvious negative prognostic factor of breast cancer. It is correlated with higher grade, node positivity, increased Ki67 index, positive HER2 status and poorer prognosis supplemented with the antiapoptotic effect that plays role in reduced chemosensitivity (12,20,(30)(31)(32)(33)(34). Diem Vo et al concluded that CD10 expression in stroma may function as a powerful prognostic factor for invasive breast cancer disease-free survival rates, and in predicting potential recurrence (35).…”

Section: Discussionmentioning

confidence: 99%

Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy

Oláh¹,

Majlat²,

Kószó³

et al. 2023

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Background: The therapeutic strategy of invasive breast cancer is based on routine histopathological markers (estrogen-, progesterone receptor, HER2, Ki67) routinely evaluated in tumor cells. However, the assessment of cancer stroma could influence therapeutic strategies. Studies have shown that stromal expression of CD10, a zinc-dependent metalloproteinase, is associated with biological aggressiveness of the tumor. In the present retrospective study, we aimed to evaluate stromal CD10 expression and association between CD10 expression and response to neoadjuvant chemotherapy in invasive breast cancer.Methods: CD10 immunohistochemistry was performed on core biopsies taken before the neoadjuvant therapy. Stromal CD10 expression was determined and compared with well-known predictive and prognostic tissue markers as well as with the following groups defined according to the degree of tumor response: no regression, partial regression, and complete regression.Results: A total of 60 locally advanced invasive breast carcinomas of “no special type” were included. The proportion of CD10 positive tumors was significantly higher in the “no regression” group compared to “complete regression” group (p = 0.000). Stromal CD10 expression was found to be significantly associated with decrease in response to neoadjuvant chemotherapy. According to CD10 expression we did not find any difference in hormone receptor status, Ki67, tumor grade or neostromal area.Conclusion: Our data suggest that CD10 expression can serve as a predictive marker of the effect of neoadjuvant chemotherapy in breast cancer patients. Therefore, its inclusion into the routine assessment of biopsies to tailor tumor-specific therapeutic strategies merits consideration.

show abstract

“…CD10 is an antigen found on the surface of specific cells, including stromal cells in fibroadenomas. Its variable expression pattern can aid pathologists in confirming the diagnosis of fibroadenomas and distinguishing them from other entities with distinct IHC profiles [ 24 ].…”

Section: Reviewmentioning

confidence: 99%

A Comprehensive Review of Breast Fibroadenoma: Correlating Clinical and Pathological Findings

Ramala,

Chandak,

Chandak

et al. 2023

Cureus

View full text Add to dashboard Cite

Breast fibroadenomas, common benign conditions, exhibit distinct clinical and histopathological features. This review highlights clinical presentation and histology correlations, providing insights for healthcare providers. Palpable masses, pain, and changes in breast appearance align with glandular and stromal components, emphasizing accurate diagnosis. Mammography, ultrasound, and MRI guide tailored treatment decisions. Challenges in differentiating atypical fibroadenomas highlight the need for meticulous histopathological evaluation. Clinical implications stress patient-centered care, shared decision-making, and ongoing follow-up. Future research focuses on genetic investigations and long-term studies. A multidisciplinary approach to breast fibroadenomas ensures comprehensive care for improved outcomes in both medical and emotional aspects.

show abstract

Stromal expression of CD10 in breast carcinoma and its correlation with clinicopathological parameters

Cited by 12 publications

References 13 publications

CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage

CD10 expression in urinary bladder urothelial carcinoma is associated with high-tumor grade and stage

Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy

A Comprehensive Review of Breast Fibroadenoma: Correlating Clinical and Pathological Findings

Contact Info

Product

Resources

About